<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">phkinetica</journal-id><journal-title-group><journal-title xml:lang="ru">Фармакокинетика и Фармакодинамика</journal-title><trans-title-group xml:lang="en"><trans-title>Pharmacokinetics and Pharmacodynamics</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2587-7836</issn><issn pub-type="epub">2686-8830</issn><publisher><publisher-name>ООО «Издательство ОКИ»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">phkinetica-181</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ИССЛЕДОВАНИЯ ФАРМАКОДИНАМИКИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACODYNAMICS STUDIES</subject></subj-group></article-categories><title-group><article-title>Нейропротективные свойства производного фурана - соединения ГИЖ-276 на модели геморрагического инсульта</article-title><trans-title-group xml:lang="en"><trans-title>Neuroprotective properties furan compounds GIZH-276 on the model of hemorrhagic stroke</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Литвинова</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Litvinova</surname><given-names>S. A.</given-names></name></name-alternatives><email xlink:type="simple">sa_litvinova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Золотов</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Zolotov</surname><given-names>N. N.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Воронина</surname><given-names>Т. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Voronina</surname><given-names>T. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кутепова</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kutepova</surname><given-names>I. S.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Жмуренко</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhmurenko</surname><given-names>L. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «НИИ фармакологии имени В.В. Закусова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>FSBI «Zakusov Institute of Pharmacology»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>09</day><month>09</month><year>2016</year></pub-date><volume>0</volume><issue>3</issue><fpage>31</fpage><lpage>33</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Литвинова С.А., Золотов Н.Н., Воронина Т.А., Кутепова И.С., Жмуренко Л.А., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Литвинова С.А., Золотов Н.Н., Воронина Т.А., Кутепова И.С., Жмуренко Л.А.</copyright-holder><copyright-holder xml:lang="en">Litvinova S.A., Zolotov N.N., Voronina T.A., Kutepova I.S., Zhmurenko L.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacokinetica.ru/jour/article/view/181">https://www.pharmacokinetica.ru/jour/article/view/181</self-uri><abstract/><trans-abstract xml:lang="en"><p>The study of the neuroprotective properties new original compound GIZH-276 and evaluate changes activities of prolyl endopeptidase (PEP) and lactate dehydrogenase (LDH) in blood plasma of rats with post-traumatic hematoma (model of hemorrhagic stroke) is the aim of this investigation. Methodology of the study: Modeling of hemorrhagic stroke (HS) was carried out using the creation of intracerebral post-traumatic hematoma with the introduction of autologous blood into the site of injury. Assay of enzymes activities in plasma was carried out with fluorescent (PEP) and ultraviolet (LDH) methods. The results of the study: GIZH-276 at dose of 10 mg/kg (7 days, intraperitoneally) has a pronounced neuroprotective effect, attenuating neurological deficits in rats with hemorrhagic stroke 24 hours, 7 and 14 days after surgery and statistically significantly increasing the number of surviving rats by 14 days of observation. The weakening of neurological deficit and death of animals is accompanied by decreased activity of enzymes LDH and PEP, which indicates the improvement of security of brain tissue oxygen and reducing neuroinflammation. Conclusion: Safety and neuroprotective effect of GIZH-276 on the model of hemorrhagic stroke may be partially due to positive effect on inflammatory and hypoxia during the development of secondary brain damage in stroke.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ГИЖ-276</kwd><kwd>геморрагический инсульт</kwd><kwd>ишемия</kwd><kwd>гипоксия</kwd><kwd>ЛДГ</kwd><kwd>ПЭП</kwd><kwd>нейровоспаление</kwd><kwd>GIZH-276</kwd><kwd>hemorrhagic stroke</kwd><kwd>ischemia</kwd><kwd>hypoxia</kwd><kwd>LDH</kwd><kwd>PEP</kwd><kwd>neuroinflamation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Т.А., Островская Р.У., Гарибова Т.Л. Методические рекомендации по доклиническому изучению лекарственных средств с ноотропным типом действия, «Руководство по проведению доклинических исследований лекарственных средств», Издание ФГБУ «НЦЭМСП» Минздравсоцразвития России, Москва, 2012; 1 (17): 276-296.</mixed-citation><mixed-citation xml:lang="en">Воронина Т.А., Островская Р.У., Гарибова Т.Л. Методические рекомендации по доклиническому изучению лекарственных средств с ноотропным типом действия, «Руководство по проведению доклинических исследований лекарственных средств», Издание ФГБУ «НЦЭМСП» Минздравсоцразвития России, Москва, 2012; 1 (17): 276-296.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Воронина Т.А., Середенин С.Б., Яркова М.А., Воронин М.В. Методические рекомендации по доклиническому изучению транквилизирующего (анксиолитического) действия лекарственных средств. Руководство по проведению доклинических исследований лекарственных средств. Часть 1, М.: изд-во «Гриф и К» ФГБУ «НЦЭМСП» Минздравсоцразвития России, 2012; 1 (14): 264-275.</mixed-citation><mixed-citation xml:lang="en">Воронина Т.А., Середенин С.Б., Яркова М.А., Воронин М.В. Методические рекомендации по доклиническому изучению транквилизирующего (анксиолитического) действия лекарственных средств. Руководство по проведению доклинических исследований лекарственных средств. Часть 1, М.: изд-во «Гриф и К» ФГБУ «НЦЭМСП» Минздравсоцразвития России, 2012; 1 (14): 264-275.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ганнушкина И.В. Патофизиологические механизмы нарушений мозгового кровообращения и новые направления в их профилактике и лечении. Журн. неврол. и психиатр. 1996; 1: 14-18.</mixed-citation><mixed-citation xml:lang="en">Ганнушкина И.В. Патофизиологические механизмы нарушений мозгового кровообращения и новые направления в их профилактике и лечении. Журн. неврол. и психиатр. 1996; 1: 14-18.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мирзоян Р.С., Плотникова М.Б., Ганьшина Т.С. и др. Методические рекомендации по доклиническому изучению лекарственных средств для лечения нарушений мозгового кровообращения и мигрени. «Руководство по проведению доклинических исследований лекарственных средств», Издание ФГБУ «НЦЭМСП» Минздравсоцразвития России, М.: 2012; 1 (28): 480-487.</mixed-citation><mixed-citation xml:lang="en">Мирзоян Р.С., Плотникова М.Б., Ганьшина Т.С. и др. Методические рекомендации по доклиническому изучению лекарственных средств для лечения нарушений мозгового кровообращения и мигрени. «Руководство по проведению доклинических исследований лекарственных средств», Издание ФГБУ «НЦЭМСП» Минздравсоцразвития России, М.: 2012; 1 (28): 480-487.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Männistö P.T., Venäläinen J., Jalkanen A., Garcia-Horsman, J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug news &amp; perspectives. 2007; 20 (5): 293-305.</mixed-citation><mixed-citation xml:lang="en">Männistö P.T., Venäläinen J., Jalkanen A., Garcia-Horsman, J.A. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug news &amp; perspectives. 2007; 20 (5): 293-305.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Turner R.J., Vink R. The Role of Substance P in Ischaemic Brain Injury. Brain Sci. 2013; 3 (1): 123-142.</mixed-citation><mixed-citation xml:lang="en">Turner R.J., Vink R. The Role of Substance P in Ischaemic Brain Injury. Brain Sci. 2013; 3 (1): 123-142.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Röhnert P., Schröder U.H., Ziabreva I., Täger M., Reymann K.G., Striggow F. Insufficient endogenous redox buffer capacity may underlie neuronal vulnerability to cerebral ischemia and reperfusion. J Neurosci Res. 2012; 90 (1): 193-202.</mixed-citation><mixed-citation xml:lang="en">Röhnert P., Schröder U.H., Ziabreva I., Täger M., Reymann K.G., Striggow F. Insufficient endogenous redox buffer capacity may underlie neuronal vulnerability to cerebral ischemia and reperfusion. J Neurosci Res. 2012; 90 (1): 193-202.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Yoshimasa Takeda, Liang Zhao, Michael Jacewicz, William A Pulsinelli, and Thaddeus S Nowak, Jr. // Metabolic and perfusion responses to recurrent peri-infarct depolarization during focal ischemia in the Spontaneously Hypertensive Rat: dominant contribution of sporadic CBF decrements to infarct expansion. J Cereb Blood Flow Metab. 2011; 31 (9): 1863-1873.</mixed-citation><mixed-citation xml:lang="en">Yoshimasa Takeda, Liang Zhao, Michael Jacewicz, William A Pulsinelli, and Thaddeus S Nowak, Jr. // Metabolic and perfusion responses to recurrent peri-infarct depolarization during focal ischemia in the Spontaneously Hypertensive Rat: dominant contribution of sporadic CBF decrements to infarct expansion. J Cereb Blood Flow Metab. 2011; 31 (9): 1863-1873.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
